{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:55:39Z","timestamp":1793944539317,"version":"4.8.0"},"reference-count":303,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The number of deaths from colorectal cancer in Japan continues to increase. Colorectal cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of treatments was performed, with corrections and additions made based on knowledge acquired since the 2016 version (drug therapy) and the 2014 version (other treatments). The Japanese Society for Cancer of the Colon and Rectum guidelines 2019 for the treatment of colorectal cancer (JSCCR guidelines 2019) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment and to deepen mutual understanding between healthcare professionals and patients by making these guidelines available to the general public. These guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. Controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSCCR guidelines 2019.<\/jats:p>","DOI":"10.1007\/s10147-019-01485-z","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T14:09:22Z","timestamp":1560607762000},"page":"1-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1708,"title":["Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6178-2574","authenticated-orcid":false,"given":"Yojiro","family":"Hashiguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Ajioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinichi","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihide","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kinugasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Murofushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Itabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uetake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Kotake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japanese Society for Cancer of the Colon and Rectum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"1485_CR1","volume-title":"JSCCR guidelines 2016 for the treatment of colorectal cancer","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2016","unstructured":"Japanese Society for Cancer of the Colon and Rectum (2016) JSCCR guidelines 2016 for the treatment of colorectal cancer. Kanehara & Co., Ltd., Tokyo"},{"key":"1485_CR2","volume-title":"Japanese classification of colorectal, appendiceal, and anal carcinoma, third","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2019","unstructured":"Japanese Society for Cancer of the Colon and Rectum (2019) Japanese classification of colorectal, appendiceal, and anal carcinoma, third, English edn. Kanehara & CO., Ltd., Tokyo","edition":"English"},{"key":"1485_CR3","volume-title":"Minds handbook for clinical practice guideline development 2014","author":"T Fukui","year":"2014","unstructured":"Fukui T, Yamaguchi N, Morizane T (2014) Minds handbook for clinical practice guideline development 2014. Igaku Shoin, Tokyo"},{"key":"1485_CR4","volume-title":"GRADE system for clinical practice guideline-therapeutic intervention","author":"M Aihara","year":"2010","unstructured":"Aihara M, Mihara H, Murayama T (2010) GRADE system for clinical practice guideline-therapeutic intervention. Toppan Media, Hirosaki"},{"key":"1485_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1472-6963-4-38","volume":"4","author":"D Atkins","year":"2004","unstructured":"Atkins D, Eccles M, Flottorp S et al (2004) Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 4:38","journal-title":"BMC Health Serv Res"},{"key":"1485_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"1485_CR7","first-page":"995998","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2008) What is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ 336:995998","journal-title":"BMJ"},{"key":"1485_CR8","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","volume":"336","author":"HJ Schunemann","year":"2008","unstructured":"Schunemann HJ, Oxman AD, Brozek J et al (2008) Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336:1106\u20131110","journal-title":"BMJ"},{"key":"1485_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/bmj.39504.506319.80","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2008) Incorporating considerations of resources use into grading recommendations. BMJ 336:1170\u20131173","journal-title":"BMJ"},{"key":"1485_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2008) Going from evidence to recommendations. BMJ 336:1049\u20131051","journal-title":"BMJ"},{"key":"1485_CR11","doi-asserted-by":"publisher","first-page":"a744","DOI":"10.1136\/bmj.a744","volume":"337","author":"R Jaeschke","year":"2008","unstructured":"Jaeschke R, Guyatt GH, Dellinger P et al (2008) Use of GRADE grid to reach decisions on clinical practice guide- lines when consensus is elusive. BMJ 337:a744","journal-title":"BMJ"},{"key":"1485_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383\u2013394","journal-title":"J Clin Epidemiol"},{"key":"1485_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 2. Framing the question and deciding on important out-comes. J Clin Epidemiol 64:395\u2013400","journal-title":"J Clin Epidemiol"},{"key":"1485_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401\u2013406","journal-title":"J Clin Epidemiol"},{"key":"1485_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Vist G et al (2011) GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 64:407\u2013415","journal-title":"J Clin Epidemiol"},{"key":"1485_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Montori V et al (2011) GRADE guidelines: 5. Rating the quality of evidence-publication bias. J Clin Epidemiol 64:1277\u20131282","journal-title":"J Clin Epidemiol"},{"key":"1485_CR17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 64:1283\u20131293","journal-title":"J Clin Epidemiol"},{"key":"1485_CR18","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 64:1294\u20131302","journal-title":"J Clin Epidemiol"},{"key":"1485_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 8. Rating the quality of evidence-indirectness. J Clin Epidemiol 64:1303\u20131310","journal-title":"J Clin Epidemiol"},{"key":"1485_CR20","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sultan S et al (2011) GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64:1311\u20131316","journal-title":"J Clin Epidemiol"},{"key":"1485_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2012.04.012","volume":"66","author":"M Brunetti","year":"2013","unstructured":"Brunetti M, Shemilt I, Pregno S et al (2013) GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 66:140\u2013150","journal-title":"J Clin Epidemiol"},{"key":"1485_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","volume":"66","author":"G Guyatt","year":"2013","unstructured":"Guyatt G, Oxman AD, Sultan S et al (2013) GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 66:151\u2013157","journal-title":"J Clin Epidemiol"},{"key":"1485_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Oxman AD, Santesso N et al (2013) GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 66:158\u2013172","journal-title":"J Clin Epidemiol"},{"key":"1485_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH, Thorlund K, Oxman AD et al (2013) GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 66:173\u2013183","journal-title":"J Clin Epidemiol"},{"key":"1485_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66:719\u2013725","journal-title":"J Clin Epidemiol"},{"key":"1485_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Schunemann HJ, Oxman AD et al (2013) GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol 66:726\u2013735","journal-title":"J Clin Epidemiol"},{"key":"1485_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/den.13065","volume":"30","author":"M Iwatate","year":"2018","unstructured":"Iwatate M, Sano Y, Tanaka S et al (2018) Validation study for development of the Japan NBI Expert Team classification of colorectal lesions. Dig Endosc 30:642\u2013651","journal-title":"Dig Endosc"},{"key":"1485_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0016-5107(98)70004-5","volume":"48","author":"Y Saitoh","year":"1998","unstructured":"Saitoh Y, Obara T, Watari J et al (1998) Invasion depth diagnosis of depressed type early colorectal cancers by combined use of videoendoscopy and chromoendoscopy. Gastrointest Endosc 48:362\u2013370","journal-title":"Gastrointest Endosc"},{"key":"1485_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1148\/radiology.205.1.9314964","volume":"205","author":"J Watari","year":"1997","unstructured":"Watari J, Saitoh Y, Obara T et al (1997) Early nonpolypoid colorectal cancer: radiographic diagnosis of depth of invasion. Radiology 205:67\u201374","journal-title":"Radiology"},{"key":"1485_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.gie.2006.06.007","volume":"64","author":"S Tanaka","year":"2006","unstructured":"Tanaka S, Kaltenbach T, Chayama K et al (2006) High-magnification colonoscopy (with videos). Gastrointest Endosc 64:604\u2013613","journal-title":"Gastrointest Endosc"},{"key":"1485_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00535-008-2223-4","volume":"43","author":"S Tanaka","year":"2008","unstructured":"Tanaka S, Oka S, Chayama K (2008) Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection. J Gastroenterol 43:641\u2013651","journal-title":"J Gastroenterol"},{"key":"1485_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1443-1661.2010.01072.x","volume":"23","author":"S Oka","year":"2011","unstructured":"Oka S, Tanaka S, Kanao H et al (2011) Mid-term prognosis after endoscopic resection for submucosal colorectal carcinoma: summary of a multicenter questionnaire survey conducted by the colorectal endoscopic resection standardization implementation working group in Japanese Society for Cancer of the Colon and Rectum. Dig Endosc 23:190\u2013194","journal-title":"Dig Endosc"},{"key":"1485_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/den.12456","volume":"27","author":"S Tanaka","year":"2015","unstructured":"Tanaka S, Kashida H, Saito Y et al (2015) JGES guidelines for colorectal endoscopic submucosal dissection\/endoscopic mucosal resection. Dig Endosc 27:417\u2013434","journal-title":"Dig Endosc"},{"key":"1485_CR34","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00384-014-1885-z","volume":"29","author":"K Kotake","year":"2014","unstructured":"Kotake K, Mizuguchi T, Moritani K et al (2014) Impact of D3 lymph node dissection on survival for patients with T3 and T4 colon cancer. Int J Colorectal Dis 29:847\u2013852","journal-title":"Int J Colorectal Dis"},{"key":"1485_CR35","unstructured":"Japanese Society for Cancer of the Colon and Rectum: Multi-institutional registry of large bowel cancer in Japan (2012) Cases treated in 2000\u20132002, vol 29 (2011), cases treated in 2003\u20132004, vol 30 (2012)"},{"key":"1485_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/bjs.1800691019","volume":"69","author":"RJ Heald","year":"1982","unstructured":"Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 69:613\u2013616","journal-title":"Br J Surg"},{"key":"1485_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0140-6736(93)90207-W","volume":"341","author":"JK MacFarlane","year":"1993","unstructured":"MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457\u2013460","journal-title":"Lancet"},{"key":"1485_CR38","first-page":"335","volume":"181","author":"WE Enker","year":"1995","unstructured":"Enker WE, Thaler HT, Cranor ML et al (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181:335\u2013346","journal-title":"J Am Coll Surg"},{"key":"1485_CR39","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/BF02235475","volume":"44","author":"AC Lowry","year":"2001","unstructured":"Lowry AC, Simmang CL, Boulos P et al (2001) Consensus statement of definitions for anorectal physiology and rectal cancer: report of the Tripartite Consensus Conference on Definitions for Anorectal Physiology and Rectal Cancer, Washington, D.C., May 1, 1999. Dis Colon Rectum 44:915\u2013919","journal-title":"Dis Colon Rectum"},{"key":"1485_CR40","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s10350-006-0714-z","volume":"49","author":"K Sugihara","year":"2006","unstructured":"Sugihara K, Kobayashi H, Kato T et al (2006) Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49:1663\u20131672","journal-title":"Dis Colon Rectum"},{"key":"1485_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<188::AID-CNCR3>3.0.CO;2-Q","volume":"80","author":"J Hida","year":"1997","unstructured":"Hida J, Yasutomi M, Maruyama T et al (1997) The extent of lymph node dissection for colon carcinoma: the potential impact on laparoscopic surgery. Cancer 80:188\u2013192","journal-title":"Cancer"},{"key":"1485_CR42","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s10350-004-6290-1","volume":"45","author":"C Ono","year":"2002","unstructured":"Ono C, Yoshinaga K, Enomoto M et al (2002) Discontinuous rectal cancer spread in the mesorectum and the optimal distal clearance margin in situ. Dis Colon Rectum 45:744\u2013749 (discussion 742\u2013743)","journal-title":"Dis Colon Rectum"},{"key":"1485_CR43","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1097\/DCR.0b013e318233fc4a","volume":"54","author":"Y Shimada","year":"2011","unstructured":"Shimada Y, Takii Y, Maruyama S et al (2011) Intramural and mesorectal distal spread detected by whole-mount sections in the determination of optimal distal resection margin in patients undergoing surgery for rectosigmoid or rectal cancer without preoperative therapy. Dis Colon Rectum 54:1510\u20131520","journal-title":"Dis Colon Rectum"},{"key":"1485_CR44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/1097-0142(19950801)76:3<388::AID-CNCR2820760307>3.0.CO;2-Y","volume":"76","author":"K Shirouzu","year":"1995","unstructured":"Shirouzu K, Isomoto H, Kakegawa T (1995) Distal spread of rectal cancer and optimal distal margin of resection for sphincter-preserving surgery. Cancer 76:388\u2013392","journal-title":"Cancer"},{"key":"1485_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3748\/wjg.v11.i3.319","volume":"11","author":"GP Zhao","year":"2005","unstructured":"Zhao GP, Zhou ZG, Lei WZ et al (2005) Pathological study of distal mesorectal cancer spread to determine a proper distal resection margin. World J Gastroenterol 11:319\u2013322","journal-title":"World J Gastroenterol"},{"key":"1485_CR46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/bjs.8677","volume":"99","author":"ST Martin","year":"2012","unstructured":"Martin ST, Heneghan HM, Winter DC (2012) Systematic review of outcomes after intersphincteric resection for low rectal cancer. Br J Surg 99:603\u2013612","journal-title":"Br J Surg"},{"key":"1485_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10350-005-0296-1","volume":"49","author":"J Pollack","year":"2006","unstructured":"Pollack J, Holm T, Cedermark B et al (2006) Long-term effect of preoperative radiation therapy on anorectal function. Dis Colon Rectum 49:345\u2013352","journal-title":"Dis Colon Rectum"},{"key":"1485_CR48","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/bjs.5819","volume":"94","author":"MM Lange","year":"2007","unstructured":"Lange MM, den Dulk M, Bossema ER et al (2007) Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg 94:1278\u20131284","journal-title":"Br J Surg"},{"key":"1485_CR49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/DCR.0b013e31819f5fa2","volume":"52","author":"K Yamada","year":"2009","unstructured":"Yamada K, Ogata S, Saiki Y et al (2009) Long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum 52:1065\u20131071","journal-title":"Dis Colon Rectum"},{"key":"1485_CR50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(12)70158-4","volume":"13","author":"S Fujita","year":"2012","unstructured":"Fujita S, Akasu T, Mizusawa J et al (2012) Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 13:616\u2013621","journal-title":"Lancet Oncol"},{"key":"1485_CR51","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.ejso.2016.07.010","volume":"42","author":"S Saito","year":"2016","unstructured":"Saito S, Fujita S, Mizusawa J et al (2016) Male sexual dysfunction after rectal cancer surgery: results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212. Eur J Surg Oncol 42:1851\u20131858","journal-title":"Eur J Surg Oncol"},{"key":"1485_CR52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ejso.2018.01.015","volume":"44","author":"M Ito","year":"2018","unstructured":"Ito M, Kobayashi A, Fujita S et al (2018) Urinary dysfunction after rectal cancer surgery: results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212). Eur J Surg Oncol 44:463\u2013468","journal-title":"Eur J Surg Oncol"},{"key":"1485_CR53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1072-7515(02)01235-8","volume":"195","author":"E de Santibanes","year":"2002","unstructured":"de Santibanes E, Lassalle FB, McCormack L et al (2002) Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. J Am Coll Surg 195:196\u2013202","journal-title":"J Am Coll Surg"},{"key":"1485_CR54","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00384-017-2806-8","volume":"32","author":"N Nakai","year":"2017","unstructured":"Nakai N, Yamaguchi T, Kinugasa Y et al (2017) Long-term outcomes after resection of para-aortic lymph node metastasis from left-sided colon and rectal cancer. Int J Colorectal Dis 32:999\u20131007","journal-title":"Int J Colorectal Dis"},{"key":"1485_CR55","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1245\/s10434-009-0692-1","volume":"16","author":"BS Min","year":"2009","unstructured":"Min BS, Kim JS, Kim NK et al (2009) Extended lymph node dissection for rectal cancer with radiologically diagnosed extramesenteric lymph node metastasis. Ann Surg Oncol 16:3271\u20133278","journal-title":"Ann Surg Oncol"},{"key":"1485_CR56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jso.21421","volume":"101","author":"PW Choi","year":"2010","unstructured":"Choi PW, Kim HC, Kim AY et al (2010) Extensive lymphadenectomy in colorectal cancer with isolated para-aortic lymph node metastasis below the level of renal vessels. J Surg Oncol 101:66\u201371","journal-title":"J Surg Oncol"},{"key":"1485_CR57","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000439547","volume":"32","author":"A Arimoto","year":"2015","unstructured":"Arimoto A, Uehara K, Kato T et al (2015) Clinical significance of para-aortic lymph node dissection for advanced or metastatic colorectal cancer in the current era of modern chemotherapy. Dig Surg 32:439\u2013444","journal-title":"Dig Surg"},{"key":"1485_CR58","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1245\/s10434-015-5027-9","volume":"23","author":"SU Bae","year":"2016","unstructured":"Bae SU, Han YD, Cho MS et al (2016) Oncologic outcomes of colon cancer patients with extraregional lymph node metastasis: comparison of isolated paraaortic lymph node metastasis with resectable liver metastasis. Ann Surg Oncol 23:1562\u20131568","journal-title":"Ann Surg Oncol"},{"key":"1485_CR59","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1086::AID-CNCR6>3.0.CO;2-6","volume":"83","author":"S Murata","year":"1998","unstructured":"Murata S, Moriya Y, Akasu T et al (1998) Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 83:1086\u20131093","journal-title":"Cancer"},{"key":"1485_CR60","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0022-5223(99)70106-6","volume":"118","author":"K Kobayashi","year":"1999","unstructured":"Kobayashi K, Kawamura M, Ishihara T (1999) Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 118:1090\u20131096","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1485_CR61","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0022-5223(99)70470-8","volume":"117","author":"BJ Robinson","year":"1999","unstructured":"Robinson BJ, Rice TW, Strong SA et al (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 117:66\u201375 (discussion 75\u201376)","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1485_CR62","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/archsurg.135.4.473","volume":"135","author":"LA Lambert","year":"2000","unstructured":"Lambert LA, Colacchio TA, Barth RJ Jr (2000) Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 135:473\u2013479 (discussion 479\u2013480)","journal-title":"Arch Surg"},{"key":"1485_CR63","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s11605-008-0540-9","volume":"12","author":"H Yoshidome","year":"2008","unstructured":"Yoshidome H, Kimura F, Shimizu H et al (2008) Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? J Gastrointest Surg 12:1391\u20131398","journal-title":"J Gastrointest Surg"},{"key":"1485_CR64","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1053\/j.seminoncol.2007.01.003","volume":"34","author":"R Adam","year":"2007","unstructured":"Adam R (2007) Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34:S7\u2013S11","journal-title":"Semin Oncol"},{"key":"1485_CR65","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1245\/s10434-011-2061-0","volume":"19","author":"VW Lam","year":"2012","unstructured":"Lam VW, Spiro C, Laurence JM et al (2012) A systematic review of clinical response and survival outcomes of down-sizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19:1292\u20131301","journal-title":"Ann Surg Oncol"},{"key":"1485_CR66","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/jso.20926","volume":"97","author":"BS Min","year":"2008","unstructured":"Min BS, Kim NK, Sohn SK et al (2008) Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. J Surg Oncol 97:136\u2013140","journal-title":"J Surg Oncol"},{"key":"1485_CR67","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.suronc.2016.09.008","volume":"25","author":"JS Wong","year":"2016","unstructured":"Wong JS, Tan GH, Teo MC (2016) Management of para-aortic lymph node metastasis in colorectal patients: a systemic review. Surg Oncol 25:411\u2013418","journal-title":"Surg Oncol"},{"key":"1485_CR68","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1245\/s10434-016-5732-z","volume":"24","author":"H Nagata","year":"2017","unstructured":"Nagata H, Ishihara S, Hata K et al (2017) Survival and prognostic factors for metachronous peritoneal metastasis in patients with colon cancer. Ann Surg Oncol 24:1269\u20131280","journal-title":"Ann Surg Oncol"},{"key":"1485_CR69","doi-asserted-by":"publisher","first-page":"20170422","DOI":"10.1259\/bjr.20170422","volume":"90","author":"C Franzese","year":"2017","unstructured":"Franzese C, Fogliata A, Comito T et al (2017) Stereotactic\/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol 90:20170422","journal-title":"Br J Radiol"},{"key":"1485_CR70","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/jso.24757","volume":"116","author":"Y Isozaki","year":"2017","unstructured":"Isozaki Y, Yamada S, Kawashiro S et al (2017) Carbon-ion radiotherapy for isolated para-aortic lymph node recurrence from colorectal cancer. J Surg Oncol 116:932\u2013938","journal-title":"J Surg Oncol"},{"key":"1485_CR71","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.3748\/wjg.15.6091","volume":"15","author":"MS Kim","year":"2009","unstructured":"Kim MS, Cho CK, Yang KM et al (2009) Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gastroenterol 15:6091\u20136095","journal-title":"World J Gastroenterol"},{"key":"1485_CR72","first-page":"54","volume":"179","author":"J Tschmelitsch","year":"1994","unstructured":"Tschmelitsch J, Kronberger P, Glaser K et al (1994) Survival after surgical treatment of recurrent carcinoma of the rectum. J Am Coll Surg 179:54\u201358","journal-title":"J Am Coll Surg"},{"key":"1485_CR73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1503\/cjs.025911","volume":"56","author":"PJ Tanis","year":"2013","unstructured":"Tanis PJ, Doeksen A, van Lanschot JJ (2013) Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg 56:135\u2013144","journal-title":"Can J Surg"},{"key":"1485_CR74","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1055-3207(18)30126-1","volume":"9","author":"LW Martin","year":"2000","unstructured":"Martin LW, Warren RS (2000) Current management of colorectal liver metastases. Surg Oncol Clin N Am 9:853\u2013876 (discussion 877\u2013858)","journal-title":"Surg Oncol Clin N Am"},{"issue":"1075\u20131090","key":"1485_CR75","first-page":"x","volume":"82","author":"C Penna","year":"2002","unstructured":"Penna C, Nordlinger B (2002) Colorectal metastasis (liver and lung). Surg Clin North Am 82(1075\u20131090):x\u2013xi","journal-title":"Surg Clin North Am"},{"key":"1485_CR76","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/01.sla.0000128305.90650.71","volume":"239","author":"EK Abdalla","year":"2004","unstructured":"Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection\/ablation for colorectal liver metastases. Ann Surg 239:818\u2013825 (discussion 825\u2013817)","journal-title":"Ann Surg"},{"key":"1485_CR77","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","volume":"14","author":"B Nordlinger","year":"2013","unstructured":"Nordlinger B, Sorbye H, Glimelius B et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208\u20131215","journal-title":"Lancet Oncol"},{"key":"1485_CR78","first-page":"S22","volume":"46","author":"T Kato","year":"2003","unstructured":"Kato T, Yasui K, Hirai T et al (2003) Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46:S22\u2013S31","journal-title":"Dis Colon Rectum"},{"key":"1485_CR79","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1148\/radiol.10100729","volume":"257","author":"MC Niekel","year":"2010","unstructured":"Niekel MC, Bipat S, Stoker J (2010) Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and\/or FDG PET\/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257:674\u2013684","journal-title":"Radiology"},{"key":"1485_CR80","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1001\/jama.2014.3740","volume":"311","author":"CA Moulton","year":"2014","unstructured":"Moulton CA, Gu CS, Law CH et al (2014) Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 311:1863\u20131869","journal-title":"JAMA"},{"key":"1485_CR81","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00000658-198403000-00010","volume":"199","author":"JG Fortner","year":"1984","unstructured":"Fortner JG, Silva JS, Golbey RB et al (1984) Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 199:306\u2013316","journal-title":"Ann Surg"},{"key":"1485_CR82","first-page":"278","volume":"100","author":"KS Hughes","year":"1986","unstructured":"Hughes KS, Simon R, Songhorabodi S et al (1986) Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100:278\u2013284","journal-title":"Surgery"},{"key":"1485_CR83","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/BF01655821","volume":"11","author":"H Ekberg","year":"1987","unstructured":"Ekberg H, Tranberg KG, Andersson R et al (1987) Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 11:541\u2013547","journal-title":"World J Surg"},{"key":"1485_CR84","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/hpb.12096","volume":"16","author":"N Battula","year":"2014","unstructured":"Battula N, Tsapralis D, Mayer D et al (2014) Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience. HPB (Oxford) 16:157\u2013163","journal-title":"HPB (Oxford)"},{"key":"1485_CR85","doi-asserted-by":"crossref","unstructured":"Nordinger B, Jaeck D, Guiguet M et al (1992) Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery In: Nordinger B, Jaeck D (eds) Treatment of hepatic metastases of colorectal cancer. Springer, Paris, pp 129\u201346","DOI":"10.1007\/978-3-642-51873-7_12"},{"key":"1485_CR86","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00000658-199804000-00019","volume":"227","author":"B Cady","year":"1998","unstructured":"Cady B, Jenkins RL, Steele GD Jr et al (1998) Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 227:566\u2013571","journal-title":"Ann Surg"},{"key":"1485_CR87","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00000658-199501000-00009","volume":"221","author":"J Yamamoto","year":"1995","unstructured":"Yamamoto J, Sugihara K, Kosuge T et al (1995) Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg 221:74\u201378","journal-title":"Ann Surg"},{"key":"1485_CR88","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/(SICI)1096-9098(199810)69:2<88::AID-JSO8>3.0.CO;2-X","volume":"69","author":"D Elias","year":"1998","unstructured":"Elias D, Cavalcanti A, Sabourin JC et al (1998) Results of 136 curative hepatectomies with a safety margin of less than 10\u00a0mm for colorectal metastases. J Surg Oncol 69:88\u201393","journal-title":"J Surg Oncol"},{"key":"1485_CR89","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1200\/JCO.1997.15.3.938","volume":"15","author":"Y Fong","year":"1997","unstructured":"Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938\u2013946","journal-title":"J Clin Oncol"},{"key":"1485_CR90","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/archsurg.137.7.833","volume":"137","author":"N Kokudo","year":"2002","unstructured":"Kokudo N, Miki Y, Sugai S et al (2002) Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 137:833\u2013840","journal-title":"Arch Surg"},{"key":"1485_CR91","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3109\/00365528809096972","volume":"149","author":"H Bismuth","year":"1988","unstructured":"Bismuth H, Castaing D, Traynor O (1988) Surgery for synchronous hepatic metastases of colorectal cancer. Scand J Gastroenterol Suppl 149:144\u2013149","journal-title":"Scand J Gastroenterol Suppl"},{"key":"1485_CR92","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/bjs.1800800302","volume":"80","author":"J Scheele","year":"1993","unstructured":"Scheele J (1993) Hepatectomy for liver metastases. Br J Surg 80:274\u2013276","journal-title":"Br J Surg"},{"key":"1485_CR93","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ctrv.2015.06.006","volume":"41","author":"R Adam","year":"2015","unstructured":"Adam R, de Gramont A, Figueras J et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41:729\u2013741","journal-title":"Cancer Treat Rev"},{"key":"1485_CR94","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1046\/j.1365-2168.2000.01580.x","volume":"87","author":"MS Rodgers","year":"2000","unstructured":"Rodgers MS, McCall JL (2000) Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg 87:1142\u20131155","journal-title":"Br J Surg"},{"key":"1485_CR95","first-page":"1081","volume":"84","author":"KT Beckurts","year":"1997","unstructured":"Beckurts KT, Holscher AH, Thorban S et al (1997) Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 84:1081\u20131084","journal-title":"Br J Surg"},{"key":"1485_CR96","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s005340050079","volume":"6","author":"S Nakamura","year":"1999","unstructured":"Nakamura S, Suzuki S, Konno H (1999) Resection of hepatic metastases of colorectal carcinoma: 20\u00a0years\u2019 experience. J Hepatobiliary Pancreat Surg 6:16\u201322","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"1485_CR97","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0003-4975(98)00269-0","volume":"66","author":"JF Regnard","year":"1998","unstructured":"Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214\u2013218 (discussion 218\u2013219)","journal-title":"Ann Thorac Surg"},{"key":"1485_CR98","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1200\/JCO.1994.12.7.1491","volume":"12","author":"B Nordlinger","year":"1994","unstructured":"Nordlinger B, Vaillant JC, Guiguet M et al (1994) Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 12:1491\u20131496","journal-title":"J Clin Oncol"},{"key":"1485_CR99","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0002-9610(99)00176-2","volume":"178","author":"J Yamamoto","year":"1999","unstructured":"Yamamoto J, Kosuge T, Shimada K et al (1999) Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 178:275\u2013281","journal-title":"Am J Surg"},{"key":"1485_CR100","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/00000658-200206000-00015","volume":"235","author":"H Petrowsky","year":"2002","unstructured":"Petrowsky H, Gonen M, Jarnagin W et al (2002) Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 235:863\u2013871","journal-title":"Ann Surg"},{"key":"1485_CR101","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0039-6060(01)83158-5","volume":"129","author":"S Suzuki","year":"2001","unstructured":"Suzuki S, Sakaguchi T, Yokoi Y et al (2001) Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 129:421\u2013428","journal-title":"Surgery"},{"key":"1485_CR102","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00268-001-0196-z","volume":"26","author":"S Nagakura","year":"2002","unstructured":"Nagakura S, Shirai Y, Suda T et al (2002) Multiple repeat resections of intra- and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg 26:141\u2013147","journal-title":"World J Surg"},{"key":"1485_CR103","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00268-004-7214-x","volume":"28","author":"K Tanaka","year":"2004","unstructured":"Tanaka K, Shimada H, Ohta M et al (2004) Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 28:482\u2013487","journal-title":"World J Surg"},{"key":"1485_CR104","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ejso.2006.10.016","volume":"33","author":"A Thelen","year":"2007","unstructured":"Thelen A, Jonas S, Benckert C et al (2007) Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol 33:324\u2013328","journal-title":"Eur J Surg Oncol"},{"key":"1485_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jso.20384","volume":"93","author":"P Pessaux","year":"2006","unstructured":"Pessaux P, Lermite E, Brehant O et al (2006) Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 93:1\u20137","journal-title":"J Surg Oncol"},{"key":"1485_CR106","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1245\/s10434-006-9067-z","volume":"13","author":"S Ishiguro","year":"2006","unstructured":"Ishiguro S, Akasu T, Fujimoto Y et al (2006) Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors. Ann Surg Oncol 13:1579\u20131587","journal-title":"Ann Surg Oncol"},{"key":"1485_CR107","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","volume":"14","author":"AC Tree","year":"2013","unstructured":"Tree AC, Khoo VS, Eeles RA et al (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28\u2013e37","journal-title":"Lancet Oncol"},{"key":"1485_CR108","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/1097-0142(19891001)64:7<1418::AID-CNCR2820640709>3.0.CO;2-N","volume":"64","author":"T Goya","year":"1989","unstructured":"Goya T, Miyazawa N, Kondo H et al (1989) Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 64:1418\u20131421","journal-title":"Cancer"},{"key":"1485_CR109","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/archsurg.1992.01420120037006","volume":"127","author":"PM McCormack","year":"1992","unstructured":"McCormack PM, Burt ME, Bains MS et al (1992) Lung resection for colorectal metastases. 10-year results. Arch Surg 127:1403\u20131406","journal-title":"Arch Surg"},{"key":"1485_CR110","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10350-004-6222-0","volume":"45","author":"H Ike","year":"2002","unstructured":"Ike H, Shimada H, Ohki S et al (2002) Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 45:468\u2013473 (discussion 473\u2013465)","journal-title":"Dis Colon Rectum"},{"key":"1485_CR111","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0022-5223(96)70085-5","volume":"112","author":"S Okumura","year":"1996","unstructured":"Okumura S, Kondo H, Tsuboi M et al (1996) Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 112:867\u2013874","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1485_CR112","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/0003-4975(92)91435-C","volume":"53","author":"MK McAfee","year":"1992","unstructured":"McAfee MK, Allen MS, Trastek VF et al (1992) Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 53:780\u2013785 (discussion 785\u2013786)","journal-title":"Ann Thorac Surg"},{"key":"1485_CR113","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1067\/mtc.2002.125165","volume":"124","author":"Y Saito","year":"2002","unstructured":"Saito Y, Omiya H, Kohno K et al (2002) Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 124:1007\u20131013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1485_CR114","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/jjco\/hyl076","volume":"36","author":"R Koga","year":"2006","unstructured":"Koga R, Yamamoto J, Saiura A et al (2006) Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol 36:643\u2013648","journal-title":"Jpn J Clin Oncol"},{"key":"1485_CR115","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.athoracsur.2006.02.027","volume":"82","author":"T Iizasa","year":"2006","unstructured":"Iizasa T, Suzuki M, Yoshida S et al (2006) Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 82:254\u2013260","journal-title":"Ann Thorac Surg"},{"key":"1485_CR116","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/bjs.6682","volume":"96","author":"K Watanabe","year":"2009","unstructured":"Watanabe K, Nagai K, Kobayashi A et al (2009) Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 96:1058\u20131065","journal-title":"Br J Surg"},{"key":"1485_CR117","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/SLA.0b013e31826eda3b","volume":"257","author":"T Iida","year":"2013","unstructured":"Iida T, Nomori H, Shiba M et al (2013) Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 257:1059\u20131064","journal-title":"Ann Surg"},{"key":"1485_CR118","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/bjs.4370","volume":"91","author":"Y Kanemitsu","year":"2004","unstructured":"Kanemitsu Y, Kato T, Hirai T et al (2004) Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 91:112\u2013120","journal-title":"Br J Surg"},{"key":"1485_CR119","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00595-012-0373-8","volume":"43","author":"T Hirosawa","year":"2013","unstructured":"Hirosawa T, Itabashi M, Ohnuki T et al (2013) Prognostic factors in patients undergoing complete resection of pulmonary metastases of colorectal cancer: a multi-institutional cumulative follow-up study. Surg Today 43:494\u2013499","journal-title":"Surg Today"},{"key":"1485_CR120","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1245\/s10434-012-2726-3","volume":"20","author":"M Gonzalez","year":"2013","unstructured":"Gonzalez M, Poncet A, Combescure C et al (2013) Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 20:572\u2013579","journal-title":"Ann Surg Oncol"},{"key":"1485_CR121","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jamcollsurg.2007.04.039","volume":"205","author":"G Miller","year":"2007","unstructured":"Miller G, Biernacki P, Kemeny NE et al (2007) Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 205:231\u2013238","journal-title":"J Am Coll Surg"},{"key":"1485_CR122","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/bjs.9783","volume":"102","author":"A Andres","year":"2015","unstructured":"Andres A, Mentha G, Adam R et al (2015) Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. Br J Surg 102:691\u2013699","journal-title":"Br J Surg"},{"key":"1485_CR123","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0003-4975(98)00019-8","volume":"65","author":"D Kandioler","year":"1998","unstructured":"Kandioler D, Kromer E, Tuchler H et al (1998) Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 65:909\u2013912","journal-title":"Ann Thorac Surg"},{"key":"1485_CR124","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.amjsurg.2010.08.016","volume":"202","author":"R Kanzaki","year":"2011","unstructured":"Kanzaki R, Higashiyama M, Oda K et al (2011) Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg 202:419\u2013426","journal-title":"Am J Surg"},{"key":"1485_CR125","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199002223220802","volume":"322","author":"RA Patchell","year":"1990","unstructured":"Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494\u2013500","journal-title":"N Engl J Med"},{"key":"1485_CR126","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1002\/cncr.25940","volume":"117","author":"PH Go","year":"2011","unstructured":"Go PH, Klaassen Z, Meadows MC et al (2011) Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 117:3630\u20133640","journal-title":"Cancer"},{"key":"1485_CR127","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1677::AID-CNCR6>3.0.CO;2-C","volume":"85","author":"M Wronski","year":"1999","unstructured":"Wronski M, Arbit E (1999) Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer 85:1677\u20131685","journal-title":"Cancer"},{"key":"1485_CR128","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10143-003-0299-0","volume":"27","author":"G D\u2019Andrea","year":"2004","unstructured":"D\u2019Andrea G, Isidori A, Caroli E et al (2004) Single cerebral metastasis from colorectal adenocarcinoma. Neurosurg Rev 27:55\u201357","journal-title":"Neurosurg Rev"},{"key":"1485_CR129","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<711::AID-CNCR3>3.0.CO;2-H","volume":"78","author":"GF Farnell","year":"1996","unstructured":"Farnell GF, Buckner JC, Cascino TL et al (1996) Brain metastases from colorectal carcinoma. The long term survivors. Cancer 78:711\u2013716","journal-title":"Cancer"},{"key":"1485_CR130","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-010-0214-9","volume":"101","author":"M Jung","year":"2011","unstructured":"Jung M, Ahn JB, Chang JH et al (2011) Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol 101:49\u201355","journal-title":"J Neurooncol"},{"key":"1485_CR131","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00432-008-0468-1","volume":"135","author":"G Aprile","year":"2009","unstructured":"Aprile G, Zanon E, Tuniz F et al (2009) Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol 135:451\u2013457","journal-title":"J Cancer Res Clin Oncol"},{"key":"1485_CR132","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/jso.23055","volume":"106","author":"S Noura","year":"2012","unstructured":"Noura S, Ohue M, Shingai T et al (2012) Brain metastasis from colorectal cancer: prognostic factors and survival. J Surg Oncol 106:144\u2013148","journal-title":"J Surg Oncol"},{"key":"1485_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","volume":"6","author":"B Borgelt","year":"1980","unstructured":"Borgelt B, Gelber R, Kramer S et al (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1\u20139","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1485_CR134","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0360-3016(81)90005-5","volume":"7","author":"JM Kurtz","year":"1981","unstructured":"Kurtz JM, Gelber R, Brady LW et al (1981) The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:891\u2013895","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1485_CR135","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0360-3016(94)90098-1","volume":"28","author":"JC Flickinger","year":"1994","unstructured":"Flickinger JC, Kondziolka D, Lunsford LD et al (1994) A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 28:797\u2013802","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1485_CR136","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10151-017-1707-8","volume":"21","author":"IL Silva","year":"2017","unstructured":"Silva IL, Iskandarani M, Hotouras A et al (2017) A systematic review to assess the management of patients with cerebral metastases secondary to colorectal cancer. Tech Coloproctol 21:847\u2013852","journal-title":"Tech Coloproctol"},{"key":"1485_CR137","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745\u2013751","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1485_CR138","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575\u2013582","journal-title":"Lancet Oncol"},{"key":"1485_CR139","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419\u2013425","journal-title":"J Clin Oncol"},{"key":"1485_CR140","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","volume":"363","author":"DW Andrews","year":"2004","unstructured":"Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665\u20131672","journal-title":"Lancet"},{"key":"1485_CR141","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","volume":"295","author":"H Aoyama","year":"2006","unstructured":"Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483\u20132491","journal-title":"JAMA"},{"key":"1485_CR142","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"1485_CR143","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","volume":"29","author":"DG Haller","year":"2011","unstructured":"Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465\u20131471","journal-title":"J Clin Oncol"},{"key":"1485_CR144","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.ejca.2014.05.025","volume":"50","author":"Y Shimada","year":"2014","unstructured":"Shimada Y, Hamaguchi T, Mizusawa J et al (2014) Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2\/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer 50:2231\u20132240","journal-title":"Eur J Cancer"},{"key":"1485_CR145","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/annonc\/mdu232","volume":"25","author":"M Yoshida","year":"2014","unstructured":"Yoshida M, Ishiguro M, Ikejiri K et al (2014) S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol 25:1743\u20131749","journal-title":"Ann Oncol"},{"key":"1485_CR146","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2468-1253(17)30297-2","volume":"3","author":"T Hamaguchi","year":"2018","unstructured":"Hamaguchi T, Shimada Y, Mizusawa J et al (2018) Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3:47\u201356","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1485_CR147","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF et al (2018) Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 378:1177\u20131188","journal-title":"N Engl J Med"},{"issue":"mdx440","key":"1485_CR148","first-page":"017","volume":"28","author":"T Yoshino","year":"2017","unstructured":"Yoshino T, Yamanaka T, Kotaka D et al (2017) Efficacy of 3 versus 6\u00a0months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration. An Oncol 28(mdx440):017","journal-title":"An Oncol"},{"key":"1485_CR149","doi-asserted-by":"publisher","first-page":"e000354","DOI":"10.1136\/esmoopen-2018-000354","volume":"3","author":"M Kotaka","year":"2018","unstructured":"Kotaka M, Yamanaka T, Yoshino T et al (2018) Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6\u00a0months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ESMO Open 3:e000354","journal-title":"ESMO Open"},{"key":"1485_CR150","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1093\/annonc\/mdv358","volume":"26","author":"S Sadahiro","year":"2015","unstructured":"Sadahiro S, Tsuchiya T, Sasaki K et al (2015) Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB\/III colon cancer: final results of JFMC33-0502. Ann Oncol 26:2274\u20132280","journal-title":"Ann Oncol"},{"issue":"suppl 6","key":"1485_CR151","first-page":"469PD","volume":"27","author":"S Yamaguchi","year":"2016","unstructured":"Yamaguchi S, Kunieda K, Sato T et al (2016) Phase III trial of 24\u00a0weeks vs. 48\u00a0weeks capecitabine adjuvant chemotherapy for patients with stage III colon cancer: final results of JFMC37-0801. Ann Oncol 27(suppl 6):469PD","journal-title":"Ann Oncol"},{"key":"1485_CR152","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/sj.bjc.6603686","volume":"96","author":"J Sakamoto","year":"2007","unstructured":"Sakamoto J, Hamada C, Yoshida S et al (2007) An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer 96:1170\u20131177","journal-title":"Br J Cancer"},{"key":"1485_CR153","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/annonc\/mdw162","volume":"27","author":"E Oki","year":"2016","unstructured":"Oki E, Murata A, Yoshida K et al (2016) A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II\/III rectal cancer (JFMC35-C1: ACTS-RC). Ann Oncol 27:1266\u20131272","journal-title":"Ann Oncol"},{"key":"1485_CR154","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejca.2018.03.009","volume":"96","author":"C Matsuda","year":"2018","unstructured":"Matsuda C, Ishiguro M, Teramukai S et al (2018) A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer 96:54\u201363","journal-title":"Eur J Cancer"},{"key":"1485_CR155","doi-asserted-by":"publisher","first-page":"e0162400","DOI":"10.1371\/journal.pone.0162400","volume":"11","author":"K Hasegawa","year":"2016","unstructured":"Hasegawa K, Saiura A, Takayama T et al (2016) Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS ONE 11:e0162400","journal-title":"PLoS ONE"},{"key":"1485_CR156","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bmj.321.7260.531","volume":"321","author":"PC Simmonds","year":"2000","unstructured":"Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321:531\u2013535","journal-title":"BMJ"},{"key":"1485_CR157","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278\u20131286","journal-title":"Lancet Oncol"},{"key":"1485_CR158","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371:1609\u20131618","journal-title":"N Engl J Med"},{"key":"1485_CR159","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27:1539\u20131546","journal-title":"Ann Oncol"},{"key":"1485_CR160","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","volume":"352","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413\u20131418","journal-title":"Lancet"},{"key":"1485_CR161","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/cas.12595","volume":"106","author":"H Taniguchi","year":"2015","unstructured":"Taniguchi H, Yamazaki K, Yoshino T et al (2015) Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS\/NRAS) mutation testing in colorectal cancer patients. Cancer Sci 106:324\u2013327","journal-title":"Cancer Sci"},{"key":"1485_CR162","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938\u20132947","journal-title":"J Clin Oncol"},{"key":"1485_CR163","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23\u201330","journal-title":"J Clin Oncol"},{"key":"1485_CR164","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"},{"key":"1485_CR165","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006\u20132012","journal-title":"J Clin Oncol"},{"key":"1485_CR166","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229\u2013237","journal-title":"J Clin Oncol"},{"key":"1485_CR167","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041\u20131047","journal-title":"Lancet"},{"key":"1485_CR168","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","volume":"25","author":"CS Fuchs","year":"2007","unstructured":"Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779\u20134786","journal-title":"J Clin Oncol"},{"key":"1485_CR169","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/annonc\/mdx816","volume":"29","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Denda T, Gamoh M et al (2018) S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29:624\u2013631","journal-title":"Ann Oncol"},{"key":"1485_CR170","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663\u2013671","journal-title":"J Clin Oncol"},{"key":"1485_CR171","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705","journal-title":"J Clin Oncol"},{"key":"1485_CR172","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408\u20131417","journal-title":"N Engl J Med"},{"key":"1485_CR173","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","volume":"138","author":"CH Kohne","year":"2012","unstructured":"Kohne CH, Hofheinz R, Mineur L et al (2012) First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138:65\u201372","journal-title":"J Cancer Res Clin Oncol"},{"key":"1485_CR174","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670\u20131676","journal-title":"J Clin Oncol"},{"key":"1485_CR175","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306\u20131315","journal-title":"Lancet Oncol"},{"key":"1485_CR176","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1200\/JCO.1987.5.10.1559","volume":"5","author":"N Petrelli","year":"1987","unstructured":"Petrelli N, Herrera L, Rustum Y et al (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high- dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559\u20131565","journal-title":"J Clin Oncol"},{"key":"1485_CR177","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","volume":"15","author":"A de Gramont","year":"1997","unstructured":"de Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808\u2013815","journal-title":"J Clin Oncol"},{"key":"1485_CR178","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","volume":"23","author":"HI Hurwitz","year":"2005","unstructured":"Hurwitz HI, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502\u20133508","journal-title":"J Clin Oncol"},{"key":"1485_CR179","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60\u201365","journal-title":"J Clin Oncol"},{"key":"1485_CR180","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282\u20132292","journal-title":"J Clin Oncol"},{"key":"1485_CR181","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097\u20134106","journal-title":"J Clin Oncol"},{"key":"1485_CR182","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","volume":"28","author":"NC Tebbutt","year":"2010","unstructured":"Tebbutt NC, Wilson K, Gebski VJ et al (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28:3191\u20133198","journal-title":"J Clin Oncol"},{"key":"1485_CR183","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2004.05.017","volume":"22","author":"K Shirao","year":"2004","unstructured":"Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil\/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT\/LV. J Clin Oncol 22:3466\u20133474","journal-title":"J Clin Oncol"},{"key":"1485_CR184","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","volume":"20","author":"JY Douillard","year":"2002","unstructured":"Douillard JY, Hoff PM, Skillings JR et al (2002) Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3605\u20133616","journal-title":"J Clin Oncol"},{"key":"1485_CR185","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1200\/JCO.2002.10.129","volume":"20","author":"J Carmichael","year":"2002","unstructured":"Carmichael J, Popiela T, Radstone D et al (2002) Randomized comparative study of tegafur\/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617\u20133627","journal-title":"J Clin Oncol"},{"key":"1485_CR186","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clcc.2015.12.001","volume":"15","author":"T Nishina","year":"2016","unstructured":"Nishina T, Moriwaki T, Shimada M et al (2016) Uracil-tegafur and oral leucovorin combined with bevacizumab in elderly patients (aged\u2009>\/=\u200975\u00a0years) with metastatic colorectal cancer: a multicenter, phase II trial (Joint study of bevacizumab, oral leucovorin, and uracil-tegafur in elderly patients [J-BLUE] study). Clin Colorectal Cancer 15:236\u2013242","journal-title":"Clin Colorectal Cancer"},{"key":"1485_CR187","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ejca.2015.03.007","volume":"51","author":"M Yoshida","year":"2015","unstructured":"Yoshida M, Muro K, Tsuji A et al (2015) Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer 51:935\u2013941","journal-title":"Eur J Cancer"},{"key":"1485_CR188","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1634\/theoncologist.2015-0171","volume":"20","author":"F Pietrantonio","year":"2015","unstructured":"Pietrantonio F, Cremolini C, Aprile G et al (2015) Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope. Oncologist 20:1261\u20131265","journal-title":"Oncologist"},{"key":"1485_CR189","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.ejca.2015.04.013","volume":"51","author":"J Sastre","year":"2015","unstructured":"Sastre J, Massuti B, Pulido G et al (2015) First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer 51:1371\u20131380","journal-title":"Eur J Cancer"},{"key":"1485_CR190","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after fi progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29\u201337","journal-title":"Lancet Oncol"},{"key":"1485_CR191","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/annonc\/mdv197","volume":"26","author":"S Iwamoto","year":"2015","unstructured":"Iwamoto S, Takahashi T, Tamagawa H et al (2015) FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 26:1427\u20131433","journal-title":"Ann Oncol"},{"key":"1485_CR192","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"RH Xu","year":"2018","unstructured":"Xu RH, Muro K, Morita S et al (2018) Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19:660\u2013671","journal-title":"Lancet Oncol"},{"key":"1485_CR193","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499\u2013508","journal-title":"Lancet Oncol"},{"key":"1485_CR194","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506","journal-title":"J Clin Oncol"},{"key":"1485_CR195","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853\u2013860","journal-title":"Lancet Oncol"},{"key":"1485_CR196","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","volume":"352","author":"P Rougier","year":"1998","unstructured":"Rougier P, Van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407\u20131412","journal-title":"Lancet"},{"key":"1485_CR197","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00280-017-3255-3","volume":"79","author":"H Kuramochi","year":"2017","unstructured":"Kuramochi H, Ando M, Itabashi M et al (2017) Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. Cancer Chemother Pharmacol 79:579\u2013585","journal-title":"Cancer Chemother Pharmacol"},{"key":"1485_CR198","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706\u20134713","journal-title":"J Clin Oncol"},{"key":"1485_CR199","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/cas.13098","volume":"107","author":"K Shitara","year":"2016","unstructured":"Shitara K, Yonesaka K, Denda T et al (2016) Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci 107:1843\u20131850","journal-title":"Cancer Sci"},{"key":"1485_CR200","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311\u20132319","journal-title":"J Clin Oncol"},{"key":"1485_CR201","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1470-2045(13)70163-3","volume":"14","author":"MT Seymour","year":"2013","unstructured":"Seymour MT, Brown SR, Middleton G et al (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 14:749\u2013759","journal-title":"Lancet Oncol"},{"key":"1485_CR202","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372:2509\u20132520","journal-title":"N Engl J Med"},{"key":"1485_CR203","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","volume":"21","author":"ML Rothenberg","year":"2003","unstructured":"Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059\u20132069","journal-title":"J Clin Oncol"},{"key":"1485_CR204","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539\u20131544","journal-title":"J Clin Oncol"},{"key":"1485_CR205","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/annonc\/mdn370","volume":"19","author":"ML Rothenberg","year":"2008","unstructured":"Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720\u20131726","journal-title":"Ann Oncol"},{"key":"1485_CR206","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"1485_CR207","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048","journal-title":"N Engl J Med"},{"key":"1485_CR208","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757\u20131765","journal-title":"N Engl J Med"},{"key":"1485_CR209","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658\u20131664","journal-title":"J Clin Oncol"},{"key":"1485_CR210","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626\u20131634","journal-title":"J Clin Oncol"},{"key":"1485_CR211","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"},{"key":"1485_CR212","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13:993\u20131001","journal-title":"Lancet Oncol"},{"key":"1485_CR213","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919","journal-title":"N Engl J Med"},{"key":"1485_CR214","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu J, Kim TW, Shen L et al (2018) Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA Study. J Clin Oncol 36:350\u2013358","journal-title":"J Clin Oncol"},{"key":"1485_CR215","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/j.1349-7006.2011.02030.x","volume":"102","author":"T Satoh","year":"2011","unstructured":"Satoh T, Ura T, Yamada Y et al (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and\/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868\u20131873","journal-title":"Cancer Sci"},{"key":"1485_CR216","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.clcc.2018.01.011","volume":"17","author":"E Oki","year":"2018","unstructured":"Oki E, Kato T, Bando H et al (2018) A multicenter clinical phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO Study. Clin Colorectal Cancer 17:147\u2013155","journal-title":"Clin Colorectal Cancer"},{"key":"1485_CR217","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/88.5.252","volume":"88","author":"P Piedbois","year":"1996","unstructured":"Meta-Analysis Group in C, Piedbois P, Buyse M et al (1996) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252\u2013258","journal-title":"J Natl Cancer Inst"},{"key":"1485_CR218","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Arnold D, Taniguchi H et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44\u201370","journal-title":"Ann Oncol"},{"key":"1485_CR219","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1111\/cas.13617","volume":"109","author":"K Yamazaki","year":"2018","unstructured":"Yamazaki K, Taniguchi H, Yoshino T et al (2018) Japanese Society of medical oncology clinical guidelines: molecular testing for colorectal cancer treatment, third edition. Cancer Sci 109:2074\u20132079","journal-title":"Cancer Sci"},{"key":"1485_CR220","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY et al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713\u20131729","journal-title":"Ann Oncol"},{"key":"1485_CR221","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/bjc.2011.19","volume":"104","author":"T Yokota","year":"2011","unstructured":"Yokota T, Ura T, Shibata N et al (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104:856\u2013862","journal-title":"Br J Cancer"},{"key":"1485_CR222","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12885-015-1276-z","volume":"15","author":"A Kawazoe","year":"2015","unstructured":"Kawazoe A, Shitara K, Fukuoka S et al (2015) A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 15:258","journal-title":"BMC Cancer"},{"key":"1485_CR223","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2013.08.024","volume":"50","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Salvatore L et al (2014) FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 50:57\u201363","journal-title":"Eur J Cancer"},{"key":"1485_CR224","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2159-8290.CD-16-0795","volume":"7","author":"R van Geel","year":"2017","unstructured":"van Geel R, Tabernero J, Elez E et al (2017) A phase Ib Dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov 7:610\u2013619","journal-title":"Cancer Discov"},{"key":"1485_CR225","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andre T, Atreya CE et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8:428\u2013443","journal-title":"Cancer Discov"},{"key":"1485_CR226","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18:1182\u20131191","journal-title":"Lancet Oncol"},{"key":"1485_CR227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23922\/jarc.2017-028","volume":"2","author":"H Ishida","year":"2018","unstructured":"Ishida H, Yamaguchi T, Tanakaya K et al (2018) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the clinical practice of hereditary colorectal cancer (translated version). J Anus Rectum Colon 2:1\u201351","journal-title":"J Anus Rectum Colon"},{"key":"1485_CR228","first-page":"1271","volume-title":"Cancer: principles and practice of oncology","author":"JMHP Skibber","year":"2001","unstructured":"Skibber JMHP, Minsky BD (2001) Cancer of the rectum. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 1271\u20131318","edition":"6"},{"key":"1485_CR229","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJM199704033361402","volume":"336","author":"Swedish Rectal Cancer Trial","year":"1997","unstructured":"Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980\u2013987","journal-title":"N Engl J Med"},{"key":"1485_CR230","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jama.284.8.1008","volume":"284","author":"C Camma","year":"2000","unstructured":"Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284:1008\u20131015","journal-title":"JAMA"},{"key":"1485_CR231","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0140-6736(01)06409-1","volume":"358","author":"Adjuvant radiotherapy for rectal cancer","year":"2001","unstructured":"Adjuvant radiotherapy for rectal cancer (2001) a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358:1291\u20131304","journal-title":"Lancet"},{"key":"1485_CR232","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638\u2013646","journal-title":"N Engl J Med"},{"key":"1485_CR233","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/01.sla.0000257358.56863.ce","volume":"246","author":"KC Peeters","year":"2007","unstructured":"Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6\u00a0years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693\u2013701","journal-title":"Ann Surg"},{"key":"1485_CR234","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1200\/JCO.2005.05.256","volume":"23","author":"CA Marijnen","year":"2005","unstructured":"Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847\u20131858","journal-title":"J Clin Oncol"},{"key":"1485_CR235","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2005.14.779","volume":"23","author":"KC Peeters","year":"2005","unstructured":"Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J Clin Oncol 23:6199\u20136206","journal-title":"J Clin Oncol"},{"key":"1485_CR236","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1200\/JCO.1999.17.8.2396","volume":"17","author":"Y Francois","year":"1999","unstructured":"Francois Y, Nemoz CJ, Baulieux J et al (1999) Infl of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17:2396","journal-title":"J Clin Oncol"},{"key":"1485_CR237","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114\u20131123","journal-title":"N Engl J Med"},{"key":"1485_CR238","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP Gerard","year":"2006","unstructured":"Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620\u20134625","journal-title":"J Clin Oncol"},{"key":"1485_CR239","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/bjs.5506","volume":"93","author":"K Bujko","year":"2006","unstructured":"Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215\u20131223","journal-title":"Br J Surg"},{"key":"1485_CR240","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","volume":"30","author":"SY Ngan","year":"2012","unstructured":"Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30:3827\u20133833","journal-title":"J Clin Oncol"},{"key":"1485_CR241","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731\u20131740","journal-title":"N Engl J Med"},{"key":"1485_CR242","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13:579\u2013588","journal-title":"Lancet Oncol"},{"key":"1485_CR243","doi-asserted-by":"crossref","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ et al (2015) Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase III randomized clinical trial. J Natl Cancer Inst 2015:107","DOI":"10.1093\/jnci\/djv248"},{"key":"1485_CR244","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","volume":"29","author":"C Aschele","year":"2011","unstructured":"Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773\u20132780","journal-title":"J Clin Oncol"},{"key":"1485_CR245","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","volume":"28","author":"JP Gerard","year":"2010","unstructured":"Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2. J Clin Oncol 28:1638\u20131644","journal-title":"J Clin Oncol"},{"key":"1485_CR246","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","volume":"30","author":"JP Gerard","year":"2012","unstructured":"Gerard JP, Azria D, Gourgou-Bourgade S (2012) Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30:4558\u20134565","journal-title":"J Clin Oncol"},{"key":"1485_CR247","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","volume":"13","author":"C Rodel","year":"2012","unstructured":"Rodel C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679\u2013687","journal-title":"Lancet Oncol"},{"key":"1485_CR248","unstructured":"Cancer pain relief and palliative care (1990) Report of a WHO expert committee. In: WHO Technical Report Series 804. WHO, Geneva, pp 21\u201322"},{"key":"1485_CR249","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrclinonc.2016.199","volume":"14","author":"EP van der Stok","year":"2017","unstructured":"van der Stok EP, Spaander MCW, Grunhagen DJ et al (2017) Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol 14:297\u2013315","journal-title":"Nat Rev Clin Oncol"},{"key":"1485_CR250","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1200\/JCO.2013.50.7442","volume":"31","author":"JA Meyerhardt","year":"2013","unstructured":"Meyerhardt JA, Mangu PB, Flynn PJ et al (2013) Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 31:4465\u20134470","journal-title":"J Clin Oncol"},{"key":"1485_CR251","unstructured":"National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology-colon cancer, version 3, 2018. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 7 Aug 2018"},{"key":"1485_CR252","doi-asserted-by":"publisher","first-page":"vi64","DOI":"10.1093\/annonc\/mdt354","volume":"24","author":"R. Labianca","year":"2013","unstructured":"Labianca R, Nordlinger B, Beretta GD et al (2013) Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi64\u2013vi72","journal-title":"Annals of Oncology"},{"key":"1485_CR253","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1200\/JCO.2005.04.0063","volume":"23","author":"CE Desch","year":"2005","unstructured":"Desch CE, Benson AB 3rd, Somerfield MR et al (2005) American Society of Clinical Oncology: colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 23:8512\u20138519","journal-title":"J Clin Oncol"},{"key":"1485_CR254","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/DCR.0000000000000410","volume":"58","author":"SR Steele","year":"2015","unstructured":"Steele SR, Chang GJ, Hendren S et al (2015) Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum 58:713\u2013725","journal-title":"Dis Colon Rectum"},{"key":"1485_CR255","doi-asserted-by":"publisher","first-page":"261","DOI":"10.7326\/0003-4819-136-4-200202190-00005","volume":"136","author":"RJ Green","year":"2002","unstructured":"Green RJ, Metlay JP, Propert K et al (2002) Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 136:261\u2013269","journal-title":"Ann Intern Med"},{"key":"1485_CR256","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0140-6736(99)06552-6","volume":"355","author":"JM Berman","year":"2000","unstructured":"Berman JM, Cheung RJ, Weinberg DS (2000) Surveillance after colorectal cancer resection. Lancet 355:395\u2013399","journal-title":"Lancet"},{"key":"1485_CR257","unstructured":"Japanese Society for Cancer of the Colon and Rectum (2016) JSCCR guidelines 2016 for the clinical practice of hereditary colorectal cancer. Kanehara & CO., LTD. Tokyo"},{"key":"1485_CR258","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1053\/j.gastro.2004.04.022","volume":"127","author":"H Ueno","year":"2004","unstructured":"Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385\u2013394","journal-title":"Gastroenterology"},{"key":"1485_CR259","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s00535-004-1339-4","volume":"39","author":"K Kitajima","year":"2004","unstructured":"Kitajima K, Fujimori T, Fujii S et al (2004) Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 39:534\u2013543","journal-title":"J Gastroenterol"},{"key":"1485_CR260","first-page":"783","volume":"7","author":"S Tanaka","year":"2000","unstructured":"Tanaka S, Haruma K, Oh EH et al (2000) Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 7:783\u2013788","journal-title":"Oncol Rep"},{"key":"1485_CR261","volume-title":"General rules for clinical and pathological studies on cancer of the colon, rectum and anus","author":"Japanese Society for Cancer of the Colon and Rectum","year":"1980","unstructured":"Japanese Society for Cancer of the Colon and Rectum (1980) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 2nd edn. Kanehara & CO., LTD., Tokyo","edition":"2"},{"key":"1485_CR262","volume-title":"General rules for clinical and pathological studies on cancer of the colon, rectum and anus","author":"Japanese Society for Cancer of the Colon and Rectum","year":"1994","unstructured":"Japanese Society for Cancer of the Colon and Rectum (1994) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 5th edn. Kanehara & CO., LTD., Tokyo","edition":"5"},{"key":"1485_CR263","volume-title":"JSCCR guidelines 2005 for the treatment of colorectal cancer","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2005","unstructured":"Japanese Society for Cancer of the Colon and Rectum (2005) JSCCR guidelines 2005 for the treatment of colorectal cancer. Kanehara & CO., LTD., Tokyo"},{"key":"1485_CR264","volume-title":"JSCCR guidelines 2009 for the treatment of colorectal cancer","author":"Japanese Society for Cancer of the Colon and Rectum","year":"2009","unstructured":"Japanese Society for Cancer of the Colon and Rectum (2009) JSCCR guidelines 2009 for the treatment of colorectal cancer. Kanehara & CO., LTD., Tokyo"},{"key":"1485_CR265","doi-asserted-by":"crossref","unstructured":"Ikematsu H, Yoda Y, Matsuda T et al (2013) Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology 144:551\u2013559 (quiz e14)","DOI":"10.1053\/j.gastro.2012.12.003"},{"key":"1485_CR266","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/j.1349-7006.2011.01997.x","volume":"102","author":"T Matsuda","year":"2011","unstructured":"Matsuda T, Fukuzawa M, Uraoka T et al (2011) Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study. Cancer Sci 102:1693\u20131697","journal-title":"Cancer Sci"},{"key":"1485_CR267","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00535-017-1318-1","volume":"52","author":"Y Tamaru","year":"2017","unstructured":"Tamaru Y, Oka S, Tanaka S et al (2017) Long-term outcomes after treatment for T1 colorectal carcinoma: a multicenter retrospective cohort study of Hiroshima GI Endoscopy Research Group. J Gastroenterol 52:1169\u20131179","journal-title":"J Gastroenterol"},{"key":"1485_CR268","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1055\/s-0034-1392882","volume":"47","author":"P Pimentel-Nunes","year":"2015","unstructured":"Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T et al (2015) Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47:829\u2013854","journal-title":"Endoscopy"},{"key":"1485_CR269","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00384-014-1947-2","volume":"29","author":"Y Takeuchi","year":"2014","unstructured":"Takeuchi Y, Iishi H, Tanaka S et al (2014) Factors associated with technical difficulties and adverse events of colorectal endoscopic submucosal dissection: retrospective exploratory factor analysis of a multicenter prospective cohort. Int J Colorectal Dis 29:1275\u20131284","journal-title":"Int J Colorectal Dis"},{"key":"1485_CR270","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00464-014-3799-9","volume":"29","author":"Y Wada","year":"2015","unstructured":"Wada Y, Kudo SE, Tanaka S et al (2015) Predictive factors for complications in endoscopic resection of large colorectal lesions: a multicenter prospective study. Surg Endosc 29:1216\u20131222","journal-title":"Surg Endosc"},{"key":"1485_CR271","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1007\/s00464-013-2903-x","volume":"27","author":"T Nakajima","year":"2013","unstructured":"Nakajima T, Saito Y, Tanaka S et al (2013) Current status of endoscopic resection strategy for large, early colorectal neoplasia in Japan. Surg Endosc 27:3262\u20133270","journal-title":"Surg Endosc"},{"issue":"6","key":"1485_CR272","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.gie.2010.08.004","volume":"72","author":"Y Saito","year":"2010","unstructured":"Saito Y, Uraoka T, Yamaguchi Y et al (2010) A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). Gastrointest Endosc 72(6):1217\u20131225","journal-title":"Gastrointest Endosc"},{"key":"1485_CR273","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/0002-9610(82)90018-6","volume":"144","author":"K Hojo","year":"1982","unstructured":"Hojo K, Koyama Y, Moriya Y (1982) Lymphatic spread and its prognostic value in patients with rectal cancer. Am J Surg 144:350\u2013354","journal-title":"Am J Surg"},{"key":"1485_CR274","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF02553486","volume":"32","author":"Y Moriya","year":"1989","unstructured":"Moriya Y, Hojo K, Sawada T et al (1989) Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection. Dis Colon Rectum 32:307\u2013315","journal-title":"Dis Colon Rectum"},{"key":"1485_CR275","first-page":"1871","volume":"78","author":"K Sugihara","year":"1996","unstructured":"Sugihara K, Moriya Y, Akasu T et al (1996) Pelvic autonomic nerve preservation for patients with rectal carcinoma. Oncologic and functional outcome. Cancer 78:1871\u20131880","journal-title":"Oncologic and functional outcome. Cancer"},{"key":"1485_CR276","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1007\/BF02237228","volume":"43","author":"T Takahashi","year":"2000","unstructured":"Takahashi T, Ueno M, Azekura K et al (2000) Lateral node dissection and total mesorectal excision for rectal cancer. Dis Colon Rectum 43:S59\u2013S68","journal-title":"Dis Colon Rectum"},{"key":"1485_CR277","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s004230050153","volume":"383","author":"T Mori","year":"1998","unstructured":"Mori T, Takahashi K, Yasuno M (1998) Radical resection with autonomic nerve preservation and lymph node dissection techniques in lower rectal cancer surgery and its results: the impact of lateral lymph node dissection. Langenbecks Arch Surg 383:409\u2013415","journal-title":"Langenbecks Arch Surg"},{"key":"1485_CR278","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/00000658-200108000-00008","volume":"234","author":"H Ueno","year":"2001","unstructured":"Ueno H, Mochizuki H, Hashiguchi Y et al (2001) Prognostic determinants of patients with lateral nodal involvement by rectal cancer. Ann Surg 234:190\u2013197","journal-title":"Ann Surg"},{"key":"1485_CR279","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/bjs.4975","volume":"92","author":"M Ueno","year":"2005","unstructured":"Ueno M, Oya M, Azekura K et al (2005) Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. Br J Surg 92:756\u2013763","journal-title":"Br J Surg"},{"key":"1485_CR280","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.surg.2017.02.005","volume":"162","author":"Y Kanemitsu","year":"2017","unstructured":"Kanemitsu Y, Komori K, Shida D et al (2017) Potential impact of lateral lymph node dissection (LLND) for low rectal cancer on prognoses and local control: a comparison of 2 high-volume centers in Japan that employ different policies concerning LLND. Surgery 162:303\u2013314","journal-title":"Surgery"},{"key":"1485_CR281","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/01.sla.0000225359.72553.8c","volume":"245","author":"H Ueno","year":"2007","unstructured":"Ueno H, Mochizuki H, Hashiguchi Y et al (2007) Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection. Ann Surg 245:80\u201387","journal-title":"Ann Surg"},{"key":"1485_CR282","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/SLA.0b013e3182565d9d","volume":"255","author":"T Akiyoshi","year":"2012","unstructured":"Akiyoshi T, Watanabe T, Miyata S et al (2012) Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg 255:1129\u20131134","journal-title":"Ann Surg"},{"key":"1485_CR283","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1007\/s00268-016-3444-y","volume":"40","author":"H Ozawa","year":"2016","unstructured":"Ozawa H, Kotake K, Hosaka M et al (2016) Impact of Lateral Pelvic Lymph Node Dissection on the Survival of Patients with T3 and T4 Low Rectal Cancer. World J Surg 40:1492\u20131499","journal-title":"World J Surg"},{"key":"1485_CR284","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1245\/s10434-014-3559-z","volume":"21","author":"HK Oh","year":"2014","unstructured":"Oh HK, Kang SB, Lee SM et al (2014) Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid\/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study. Ann Surg Oncol 21:2280\u20132287","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 3","key":"1485_CR285","doi-asserted-by":"publisher","first-page":"S614","DOI":"10.1245\/s10434-015-4565-5","volume":"22","author":"T Akiyoshi","year":"2015","unstructured":"Akiyoshi T, Matsueda K, Hiratsuka M et al (2015) Indications for Lateral Pelvic Lymph Node Dissection Based on Magnetic Resonance Imaging Before and After Preoperative Chemoradiotherapy in Patients with Advanced Low-Rectal Cancer. Ann Surg Oncol 22(Suppl 3):S614\u2013S620","journal-title":"Ann Surg Oncol"},{"key":"1485_CR286","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/SLA.0000000000002212","volume":"266","author":"S Fujita","year":"2017","unstructured":"Fujita S, Mizusawa J, Kanemitsu Y et al (2017) Mesorectal excision with or without lateral lymph node dissection for clinical stage II\/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg 266:201\u2013207","journal-title":"Ann Surg"},{"key":"1485_CR287","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/BF02236627","volume":"43","author":"SR Pestieau","year":"2000","unstructured":"Pestieau SR, Sugarbaker PH (2000) Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum 43:1341\u20131346 (discussion 1347\u20131348 )","journal-title":"Dis Colon Rectum"},{"key":"1485_CR288","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00595-013-0735-x","volume":"44","author":"H Ozawa","year":"2014","unstructured":"Ozawa H, Kotake K, Kobayashi H et al (2014) Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database. Surg Today 44:1643\u20131650","journal-title":"Surg Today"},{"key":"1485_CR289","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1245\/s10434-017-6133-7","volume":"25","author":"D Shida","year":"2018","unstructured":"Shida D, Tsukamoto S, Ochiai H et al (2018) Long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 25:173\u2013178","journal-title":"Ann Surg Oncol"},{"key":"1485_CR290","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1245\/s10434-018-6436-3","volume":"25","author":"D Shida","year":"2018","unstructured":"Shida D, Yoshida T, Tanabe T et al (2018) Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol 25:1646\u20131653","journal-title":"Ann Surg Oncol"},{"key":"1485_CR291","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00535-013-0820-3","volume":"49","author":"H Kobayashi","year":"2014","unstructured":"Kobayashi H, Kotake K, Funahashi K et al (2014) Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol 49:646\u2013654","journal-title":"J Gastroenterol"},{"key":"1485_CR292","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s10147-012-0505-6","volume":"19","author":"H Kobayashi","year":"2014","unstructured":"Kobayashi H, Kotake K, Sugihara K (2014) Outcomes of surgery without HIPEC for synchronous peritoneal metastasis from colorectal cancer: data from a multi-center registry. Int J Clin Oncol 19:98\u2013105","journal-title":"Int J Clin Oncol"},{"key":"1485_CR293","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2007.13.7471","volume":"26","author":"R Adam","year":"2008","unstructured":"Adam R, Wicherts DA, de Haas RJ et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26:1635\u20131641","journal-title":"J Clin Oncol"},{"key":"1485_CR294","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s11605-010-1348-y","volume":"14","author":"MG van Vledder","year":"2010","unstructured":"van Vledder MG, de Jong MC, Pawlik TM et al (2010) Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 14:1691\u20131700","journal-title":"J Gastrointest Surg"},{"key":"1485_CR295","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cncr.24912","volume":"116","author":"RC Auer","year":"2010","unstructured":"Auer RC, White RR, Kemeny NE et al (2010) Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 116:1502\u20131509","journal-title":"Cancer"},{"key":"1485_CR296","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2006.05.8727","volume":"24","author":"S Benoist","year":"2006","unstructured":"Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939\u20133945","journal-title":"J Clin Oncol"},{"key":"1485_CR297","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1091-255X(02)00121-X","volume":"7","author":"PJ Allen","year":"2003","unstructured":"Allen PJ, Kemeny N, Jarnagin W et al (2003) Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7:109\u2013117","journal-title":"J Gastrointest Surg"},{"key":"1485_CR298","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","volume":"25","author":"JP Kuebler","year":"2007","unstructured":"Kuebler JP, Wieand HS, O\u2019Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198\u20132204","journal-title":"J Clin Oncol"},{"key":"1485_CR299","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109\u20133116","journal-title":"J Clin Oncol"},{"key":"1485_CR300","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G, O\u2019Connell MJ, Allegra CJ et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768\u20133774","journal-title":"J Clin Oncol"},{"key":"1485_CR301","doi-asserted-by":"crossref","unstructured":"Efficacy of adjuvant fluorouracil and folinic acid in colon cancer (1995) International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939\u2013944","DOI":"10.1016\/S0140-6736(95)90696-7"},{"key":"1485_CR302","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696\u20132704","journal-title":"N Engl J Med"},{"key":"1485_CR303","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2005.04.7498","volume":"24","author":"BC Lembersky","year":"2006","unstructured":"Lembersky BC, Wieand HS, Petrelli NJ et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059\u20132064","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01485-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-019-01485-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01485-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T02:18:38Z","timestamp":1650161918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-019-01485-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":303,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1485"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01485-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"(1) The following corporations were disclosed by self-declaration of the Guideline Committee members and Guideline Evaluation Committee members. (2) A2 Healthcare Corp., Akita Sumitomo Co., Ltd., Array Biopharma Inc., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Covidien Japan, Inc., DAIICHI SANKYO COMPANY, Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., Intuitive Surgical, Inc., Japan Clinical Research Operations, Johnson & Johnson K.K., Kaigen Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Mediscience Planning Inc., Merck Serono Co., Ltd., Merck Biopharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MRP Co., Ltd., MSD K.K., NanoCarrier Co., Ltd., Nippon Boehringer lngelheim Co., Ltd., Olympus Corporation, Ono pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Shimadzu Corporation, Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sysmex Corporation, Taiho pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., TERUMO CORPORATION, Yakult Honsha Co., Ltd. ((2) Measures for the conflicts of interest:The Guideline Committee and the Guideline Evaluation Committee have been organized in members with a diverse range of disciplines, including surgery, internal medicine, radiology, pathology, etc., in order to minimize biased opinion. Each recommendation was made determined not on an individual opinion basis but based on voting by the whole committee members, with consensus prioritized. When voting for CQ, conflicts in relation to economic and academic interests were confirmed for each CQ, and members with conflicts of interest in the CQ abstained from voting.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}